Eli Lilly and Co. spends a lot of time these days telling the rest of the story—how well it’s doing in areas not connected to highly lucrative drugs about to see their patents expire. But for the most part, investors and analysts just want to know when the next blockbuster will be coming.
Eli Lilly and Co.’s first-quarter profit beat the expectations of Wall Street analysts, but its stock price slipped anyway Monday morning, along with the broader market.
Drivers across Indiana could be required to have their vehicles undergo emissions testing if new federal Environmental Protection Agency rules set for release this summer are strict enough, a state environmental official said.
Indianapolis-based Krieg DeVault LLP hired Jason D. Schultz as an associate in its health care practice, working from the firm’s office in Mishawaka. Schultz focuses on transactions and compliance for hospitals, physician groups, mental health facilities, radiology facilities and medical device manufacturers. He previously worked for Indianapolis-based Baker & Daniels LLP.
Indiana University Health named Dr. Douglas Schwartzentruber medical director of cancer services and associate director for clinical affairs at the IU Melvin and Bren Simon Cancer Center in Indianapolis. Schwartzentruber, a surgical oncologist, most recently was medical director of cancer care at IU Health’s hospital in Goshen. Last year he was named to Time magazine’s annual list of the 100 most influential people in the world for his research showing potential for a vaccine therapy to treat cancer. He is a graduate of the IU School of Medicine and a former research investigator at the National Cancer Institute.
IU Health hired James G. Terwilliger as vice president of cancer services for its statewide network of hospitals. Most recently, Terwilliger served as executive vice president of cancer centers at the University of Pittsburgh Medical Center. Terwilliger holds a bachelors degree from Boston University and a masters of public health from the University of California, Los Angeles.
The Indiana Health Information Exchange named Jim Hill vice president of sales. Previously, Hill was CEO of his own software company, Achievant, which provided human capital-management services. Hill holds a bachelor's degree from IU and an MBA in marketing from Butler University.
I read [Mickey Maurer’s] column in the April 4 issue. There is not one way to describe “the homeless.”
The Indiana University School of Medicine has licensed a pediatric psychiatrist’s patent on
an alcohol-dependency drug that the doctor discovered improves the language and social skills of autism patients. IU has licensed the patent to Indianapolis-based Confluence Pharmaceuticals Inc.
An Indianapolis insurance brokerage disciplined for unauthorized legal practice might now face millions of dollars in claims from more than 4,000 former clients because of a class-action suit filed in Marion Superior Court.
Meet the people who tweet for Indianapolis Symphony Orchestra, AAA, Butler University and other local businesses.
The widespread Internet posting of a letter by a retired Purdue University researcher who says he has linked genetically modified corn and soybeans to crop diseases and to abortions and infertility in livestock has raised concern among scientists that the public will believe his unsupported claim is true.
An informal collaboration of social workers, police and prosecutors has had early success getting some of the most stubborn homeless people in Indianapolis from downtown streets to shelter or recovery programs.
Tom Swoik, executive director of Illinois Casino Gaming Association, said gambling revenue has dropped 32 percent since the state’s smoking ban was approved. He said the ban has cost state government about $800 million in taxes.
China remains a small market for Eli Lilly and Co. It generated $320 million in sales for the company in 2010, just 1.3 percent of its $23 billion in sales worldwide. But Lilly has big ambitions in China and is racing to capitalize on its rapid economic growth.
Across all time and all cultures, wise leaders and wise societies have recognized that marriage is good, and wise societies have protected and nurtured it.
Even if one believes that same-sex marriages are a “problem,” enacting House Joint Resolution 6 will change nothing.
The world is caught in a dangerous feedback loop—higher oil prices and climate disruptions lead to higher food prices, higher food prices lead to more instability, more instability leads to higher oil prices.
A key financial stepping stone for Indianapolis-area startups is dwindling, with no significant replacement on the horizon.
Zimmer Holdings Inc. and Biomet Inc., both based in Warsaw, are among the bidders for AstraZeneca Plc’s Astra Tech, a Swedish unit that makes dental implants and medical devices, reported Bloomberg, citing two people with direct knowledge of the matter. Astra Tech may sell for $1.8 billion to $2.1 billion, according to a research note by analysts at Sanford C. Bernstein. Astra Tech, which also makes medical devices for urology and surgery, had sales last year of $535 million. It employs 2,200 and operates in 16 markets. Separately, Zimmer won a $13.5 million contract to sell orthopedic implants to the U.S. Department of Defense. The new contract is guaranteed for one year, with the possibility of four one-year renewals.
Elanco, the animal health unit of Indianapolis-based Eli Lilly and Co., which this month agreed to acquire Johnson & Johnson’s European animal health unit, also had its eyes on another target, according to a Reuters report. A now-abandoned joint venture between the animal health businesses of New Jersey-based Merck & Co. Inc. and France-based Sanofi-Aventis SA anticipated selling off some assets for roughly $1 billion, according to unnamed sources cited by Reuters. The news agency reported that Elanco paid roughly $300 million to Johnson & Johnson, in order to acquire 50 animal health medicines sold under the name Janssen Animal Health. Elanco is the world’s fourth-largest animal health company, with $1.4 billion in annual revenue.
How’s this for financing drug development? Even though it hadn’t brought a single product even close to the market, Carmel-based Marcadia Biotech Inc. was sitting on $37 million in cash when it agreed to sell itself in December to Switzerland-based Roche. The money piled up not from venture capitalists but through Marcadia’s research partnerships with large pharmaceutical companies, primarily with New Jersey-based Merck & Co. Inc. “Our venture-capital firms were going crazy. They never had a company that had to pay taxes,” said Fritz French, former CEO of the 11-person firm, which had attracted $15 million from investors early in its existence. French and his management team sold Marcadia for $287 million, with the possibility of reaping $250 million more if one of Marcadia’s experimental diabetes drugs makes it to market.
Elkhart General Healthcare System and Memorial Hospital and Health System of South Bend have agreed to merge. The two hospitals signed a memorandum of understanding to develop a parent organization that will operate both systems. Memorial CEO Phil Newbold will lead the combined organization. According to Newbold, the affiliation will attract more physicians to engage with the new system and help direct its future. “Together, Elkhart General and Memorial will have more than 700 highly skilled, well-trained physicians on staff. This shared medical expertise will enable us to attract even more specialized professionals to the area and produce the region’s highest quality of care,” Newbold said. Memorial Hospital boasts 526 beds. Elkhart General has 325 beds.
